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Performance Metrics in Professional Baseball
Pitchers before and after Surgical Treatment
for Neurogenic Thoracic Outlet Syndrome
Robert W. Thompson,1 Corey Dawkins,2 Chandu Vemuri,1 Michael W. Mulholland,3
Tyler D. Hadzinsky,4 and Gregory J. Pearl,5 St. Louis, Missouri, Waltham, Massachusetts,
Ann Arbor, Michigan, and Dallas, Texas

Background: High-performance throwing athletes may be susceptible to the development of
neurogenic thoracic outlet syndrome (NTOS). This condition can be career-threatening but
the outcomes of treatment for NTOS in elite athletes have not been well characterized. The purpose of this study was to utilize objective performance metrics to evaluate the impact of surgical
treatment for NTOS in Major League Baseball (MLB) pitchers.
Methods: Thirteen established MLB pitchers underwent operations for NTOS between July
2001 and July 2014. For those returning to MLB, traditional and advanced (PitchF/x) MLB performance metrics were acquired from public databases for various time-period scenarios before
and after surgery, with comparisons made using paired t-tests, Wilcoxon matched-pair signedrank tests, and KruskaleWallis analysis of variance.
Results: Ten of 13 pitchers (77%) achieved a sustained return to MLB, with a mean age of
30.2 ± 1.4 years at the time of surgery and 10.8 ± 1.5 months of postoperative rehabilitation
before the return to MLB. Pre- and postoperative career data revealed no significant differences
for 15 traditional pitching metrics, including earned run average (ERA), fielding independent
pitching, walks plus hits per inning pitched (WHIP), walks per 9 innings, and strikeouts to
walk ratio (SO/BB). There were also no significant differences between the 3 years before
and the 3 years after surgical treatment. Using PitchF/x data for 72 advanced metrics and 25
different time-period scenarios, the highest number of significant relationships (n ¼ 18) was
observed for the 8 weeks before/12 weeks after scenario. In this analysis, 54 (75%) measures
were unchanged (including ERA, WHIP, and SO/BB) and 14 (19%) were significantly improved,
while only 4 (6%) were significantly decreased (including hard pitch maximal velocity 93.1 ± 1.0
vs. 92.5 ± 0.9 miles/hr, P ¼ 0.047). Six pitchers remained active in MLB during the study period,
while the other 4 had retired due to factors or injuries unrelated to NTOS.
Conclusions: Objective performance metrics demonstrate that pitchers returning to MLB after
surgery for NTOS have had capabilities equivalent to or better than before treatment. Thoracic
outlet decompression coupled with an ample period of postoperative rehabilitation can provide
effective treatment for professional baseball pitchers with career-threatening NTOS.

Conflicts of interest: None.
1

Center for Thoracic Outlet Syndrome and Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO.
2
The Micheli Center for Sports Injury Prevention and Division of
Sports Medicine, Boston Children’s Hospital, Waltham, MA.
3

Department of Surgery, University of Michigan Medical Center,
Ann Arbor, MI.
4
Baseball Operations, St. Louis Cardinals Baseball Club, Busch Stadium, St. Louis, MO.
5
Department of Vascular Surgery, Baylor University Medical Center
and Texas A&M Health Sciences Center, Dallas, TX.

216

Correspondence to: Robert W. Thompson, MD, Center for Thoracic
Outlet Syndrome, Section of Vascular Surgery, Washington University
School of Medicine, 5101 Queeny Tower, One Barnes-Jewish Hospital
Plaza, Campus Box 8109, St. Louis, MO 63110, USA; E-mail:
thompson@wudosis.wustl.edu
Ann Vasc Surg 2017; 39: 216–227
http://dx.doi.org/10.1016/j.avsg.2016.05.103
Ó 2016 The Author(s). Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Manuscript received: May 11, 2016; manuscript accepted: May 18, 2016;
published online: 12 August 2016

Volume 39, February 2017

INTRODUCTION
Neurogenic thoracic outlet syndrome (NTOS) is a
rare and potentially disabling condition caused by
dynamic compression of the brachial plexus.1 It is
thought to be caused by predisposing variations in
anatomy combined with scalene and/or pectoralis
minor muscle hypertrophy or injury, resulting in
muscle fibrosis and excessive, sustained, muscle
spasm.1 Compression and irritation of the adjacent
brachial plexus is reflected by tenderness over the
scalene triangle and/or subcoracoid space, along
with exacerbation of upper extremity pain, numbness, and paresthesia during arm elevation.2,3
Because there are no laboratory testing approaches,
electrophysiological tests, or imaging procedures
that are sufficiently accurate to establish or dismiss
NTOS, the diagnosis is based largely on the exclusion of other conditions and a recognition of stereotypical clinical patterns.3 The initial treatment of
NTOS is almost always centered on pain management, physical therapy, and workplace ergonomic
modifications, but surgical management is recommended when there are disabling symptoms, a
sound clinical diagnosis, and a lack of satisfactory
improvement following conservative approaches.1,4
Recent studies indicate that there have been improvements in the outcome of surgical treatment for
NTOS, along with increasing evidence for enhanced
quality-of-life in surgical patients.4e7 The outcomes
of surgery for NTOS are usually measured in
conventional terms (postoperative complications,
hospital length of stay, etc.), as well as selfassessment symptom surveys, validated measurement instruments, and rates of return to work.4e7
However, such approaches may provide incomplete
assessment of results, given that patients recovered
from surgical treatment may still have intermittent
or activity-related symptoms. It is important to
continue developing new approaches to more accurately assess the functional outcomes of surgical
treatment for NTOS.
High-performance throwing athletes may be susceptible to the development of NTOS as a manifestation of repetitive strain injury and this condition has
been occasionally identified in collegiate and professional baseball players.8e12 In elite athletes, NTOS
can be a career-threatening condition and surgical
treatment may often be recommended. While excellent outcomes of surgical treatment have been
described for elite overhead athletes undergoing surgical treatment for venous TOS (subclavian vein
effort thrombosis) and forms of arterial TOS,10,13e15
the outcomes of treatment for NTOS in this unique
population have not been well characterized.
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With the advent of comprehensive pitch-by-pitch
assessment, application of complex statistical analytics, and the availability of large public databases,
a wealth of detailed information is currently available regarding baseball pitching performance at
the professional level.16e21 This information has
been used to evaluate the success rates and outcomes of treatment for other conditions, such as
reconstruction of the medial ulnar collateral ligament, yielding new insights into the value, and limitations of surgical treatment.22e26 The purpose of
this study was to utilize objective performance metrics for Major League Baseball (MLB) pitchers who
have undergone surgical treatment for NTOS, to
determine the effects of treatment on postoperative
athletic performance.

METHODS
Study Group
Professional MLB pitchers who underwent surgical
treatment for NTOS between July 2001 and July
2014 were identified from publicly available media
and MLB team injury reports. Position players with
NTOS were excluded from analysis, as were pitchers
who had undergone surgical treatment for either
arterial or venous forms of TOS. Of 13 MLB pitchers
meeting these criteria, 3 individuals did not achieve a
sustained return to play at the MLB level after surgical treatment for NTOS. The study group thereby
consisted of 10 individuals meeting the inclusion
criteria and achieving a sustained return to MLB
before October 2015. The study was determined to
be exempt from full Institutional Review Board
(IRB) review by the Washington University School
of Medicine Human Research Subjects Committee.
Sources of Data
For each study subject, individual game logs for
MLB regular season games were compared from 2
independent sources to ensure data accuracy, FanGraphs (http://www.fangraphs.com) and Brooks
Baseball (Pitch Info LLC, Chicago, IL; http://www.
brooksbaseball.net), with additional data obtained
from Baseball Reference (http://www.baseballreference.com).
Traditional Pitching Metrics
Fifteen traditional pitching metrics thought to be
potentially affected by NTOS were selected for inclusion in the study, including wineloss percentage,
strikeouts per 9 innings, walks per 9 innings (BB/
9), strikeouts per walks (SO/BB), home runs per 9
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Table I. MLB pitchers with NTOS, careers before surgical treatment
Career in MLB before surgery
Pitcher

Side

Age at debut

Days

Games

Innings

Pitches

1
2
3
4
5
6
7
8
9
10
Mean ± SEM
Median

Left
Left
Right
Right
Right
Right
Right
Right
Left
Left

24
22
23
25
25
21
23
24
24
21
23 ± 1
23.5

4485
381
103
3075
3213
4327
2869
2611
2028
2191
2528 ± 457
2740

587
26
9
358
159
315
188
308
147
106
220 ± 55
174

2242
147
52
363
890
1937
994
333
771
594
832 ± 232
683

31,039
2439
841
5818
13,473
29,344
15,294
4862
12,248
9449
12,481 ± 3309
10,849

SEM, standard error of the mean.

innings, walks per batter faced, line drives per batter
faced, walks plus hits per inning pitched (WHIP),
strikeouts per batter faced, home runs per batter
faced, home runs per flyballs plus line drives,
ground ball per batter faced, fly balls per batter
faced, earned run average (ERA), fielding independent pitching (FIP), ball percentage (B%), and strike
percentage (Str%).

Advanced Pitching Metrics
Beginning in 2006, the PitchF/x system (Sportvision,
Chicago, IL) has tracked velocity, movement, spin
rate, spin direction, and other parameters on all
pitches at the MLB level. Pitch classifications within
the PitchF/x system are based on a real-time automated neural network algorithm, but automated
classifiers can have difficulty with certain pitch types
and pitches within a player’s skill set. Brooks Baseball reports pitch classification data that Pitch Info
LLC manually reviews for each pitcher and are
confirmed by other sources including video analysis
and on-field personnel. Pitch classifications used in
this analysis included grouped pitch types (hard, offspeed, and breaking) and individual pitch types
(fourseam fastball, sinker, changeup, curveball, cutter, and split-finger). The PitchF/x metrics used for
analysis in this study included average pitch velocity
(AvgV), maximum pitch velocity (MaxV), horizontal movement, vertical movement, vertical movement plus gravity effects, grooved pitch percentage,
whiff percentage, opponents isolated percentage,
swing percent, whiffs per swing, line drives per ball
in play, ground balls per ball in play, fly balls per

ball in play, opponent batting average, and opponent
slugging percentage.
Time-Period Scenarios for Analysis
For each study subject, individual career data for
traditional pitching metrics were initially compared
from before and after the time of surgical treatment.
As NTOS presents over shorter periods of time that
may not be reflected by career data, we next examined traditional and advanced pitching metrics for
the 3 years surrounding the index (surgical treatment) year. For more detailed analysis closer to
the time of surgery, we then examined traditional
and advanced pitching metrics to compare 5
different time periods before the last game played
prior to surgery (4 weeks, 8 weeks, 12 weeks,
6 months, and 12 months) and the same 5 different
time periods after the first game back to pitching in
an official MLB game.
Statistical Methods
All statistical analyses were performed using SPSS
version 22 (IBM Corporation, Armonk, NY) or Prism
6.0 (GraphPad Software, Inc., La Jolla, CA). For
before-and-after surgery comparisons, paired
average performance data were analyzed by paired
t-tests for normally distributed data and by
Wilcoxon matched-pairs signed-rank tests for data
that were not normally distributed. Unpaired data
were analyzed using the nonparametric Manne
Whitney U-test. Multiple-group analyses were performed using the nonparametric KruskaleWallis
analysis of variance test. For all tests, a P value
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Fig. 1. Career timelines related to surgery for NTOS.
Career timelines are shown as horizontal bars for 10
MLB pitchers in relation to surgical treatment for
NTOS, from the first MLB appearance (debut) to the
end of 2015. The surgical treatment interval is divided
into the ‘‘preop’’ period (the interval between the last
MLB game appearance and surgical treatment) and the
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‘‘rehab’’ period (the interval between surgical treatment
and the first MLB game appearance following surgery).
Mean ± SEM values (months) are shown for each interval in the key (bordered inset). Current MLB playing status
as of October 2015 for each pitcher is designated as
retired (R) or active (A). SEM, standard error of the
mean.

Table II. MLB pitchers with NTOS, careers after surgical treatment
Career after return to MLB
Pitcher

Age at surgery

Rehab days

Days

Games

Innings

Pitches

Current status

1
2
3
4
5
6
7
8
9
10
Mean ± SEM
Median

36
23
23
34
34
33
31
31
30
27

246
260
281
167
306
273
636
258
509
315
30 ± 1
31.0

2357
1934
862
533
562
116
66
436
109
141
325 ± 44
277

206
109
72
50
64
20
7
79
23
20
712 ± 254
485

1253
521
446
43
288
115
35
70
42
129
65 ± 19
57

19,940
8860
7118
717
4865
1895
551
1107
671
1796
294 ± 120
122

Retired
Retired
MLB
Retired
MLB
Retired
MLB
MLB
MLB
MLB
4752 ± 1926
1846

SEM, standard error of the mean.

<0.05 was considered to indicate a statistically
significant difference.

RESULTS
The 10 pitchers included in the study had a mean
age of 23.2 ± 0.5 years at first MLB appearance

and 6.9 ± 1.3 years of playing time before treatment
for NTOS, which occurred at a mean age of
30.2 ± 1.4 years (Table I). Figure 1 illustrates the
overall career timelines for this cohort in relation
to the time of surgery for NTOS, demonstrating a
mean interval between the last MLB appearance
and surgical treatment of 4.5 ± 2.3 months and a
mean period of postoperative rehabilitation to the
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Fig. 2. Traditional pitching metrics, career. Nine relevant
traditional pitching performance metrics for 10 MLB
pitchers, comparing careers before and after surgical
treatment for NTOS. Data shown illustrate the individual
pitchers (open circles and line graphs) and group
mean ± SEM (shaded bar graphs with mean values

Annals of Vascular Surgery

indicated). Solid horizontal lines to the right of each panel
indicate the 20-year MLB average for each metric (based
on 180 innings pitched per year). There were no significant differences for any of the preop versus postop comparisons shown (Wilcoxon matched-pairs signed-rank
tests). SEM, standard error of the mean.
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Fig. 3. Traditional pitching metrics, 3 years surrounding
index year. Twelve relevant traditional pitching performance metrics for 10 MLB pitchers, comparing the
3 years before and after the index (surgical treatment)
year for NTOS. Data shown illustrate the mean ± SEM
for the group at each year surrounding the index year.
For each year, the number of evaluable individuals was

8 (Index  3), 8 (Index  2), 8 (Index  1), 7 (Index),
9 (Index + 1), 7 (Index + 2), and 3 (Index + 3). Solid horizontal lines to the right of each panel indicate the 20-year
MLB average for each metric (based on 180 innings
pitched per year). There were no significant differences
for any of the comparisons shown (KruskaleWallis analysis of variance tests). SEM, standard error of the mean.

first MLB reappearance of 10.8 ± 1.5 months.
Following the return after surgical treatment, the
pitchers in this cohort continued to play at the major
league level for a mean of 2.0 ± 0.7 years, with 6
remaining active in MLB at the close of the study
period and the other 4 individuals having retired
due to factors or injuries unrelated to NTOS.
(Table II).
Analysis of pitching performance metrics was
conducted in 3 separate stages. First, data were
compared between the preoperative and postoperative career periods for the cohort of pitchers
returning to MLB after surgery for NTOS. As

illustrated in Figure 2, this revealed no significant
differences with regard to 15 traditional pitching
metrics, including ERA, FIP, WHIP, BB/9, and
SO/BB.
In the second stage of analysis, data were examined for the 3 years before and the 3 years after
the return to MLB from surgical treatment. This
also revealed that there were no significant differences in traditional pitching metrics when
compared with the 2 time periods (Fig. 3). A complete summary of traditional and advanced pitching
metrics for the 10 individual pitchers, for the 3 years
surrounding the index (surgical treatment) year, is
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Fig. 4. Pitch velocity and movement metrics, 3 years surrounding index year. Four relevant PitchF/x advanced
pitch metrics for 9 MLB pitchers, comparing the 3 years
before and after the index (surgical treatment) year for
NTOS. Data shown illustrate the mean ± SEM for the
group at each year surrounding the index year. For

each year, the number of evaluable individuals was 7
(Index  3), 7 (Index  2), 7 (Index  1), 6 (Index), 8
(Index + 1), 6 (Index + 2), and 2 (Index + 3). There
were no significant differences for any of the comparisons shown (KruskaleWallis analysis of variance tests).
SEM, standard error of the mean.

presented in the Appendix. Figure 4 presents data
for 4 relevant PitchF/x advanced pitch metrics, for
which there were no significant differences.
In the third stage of analysis, performance data
were examined for 25 different time-period scenarios
surrounding the time of surgical treatment to
compare 72 advanced performance metrics (in total,
approximately 1800 time-period scenarios and performance metrics were used as variables for
analysis). By using paired t-tests and Wilcoxon
matched-pairs signed-rank tests, there were a total
of 247 significant relationships detected among the
permutations analyzed. The data shown in Table III
indicate the number of significant relationships
detected for different time-period scenarios, with
the 8- to 12-week scenario having the highest number (18, 25% of the 72 metrics analyzed). In assessing
the specific performance metrics for the 8- to 12-week
time-period scenario, 54 of the 72 metrics (75%)
analyzed were unchanged (including ERA, WHIP,
and SO/BB). Fourteen metrics (19%) with a significant difference represented an improvement in pitching performance after the return from surgical
treatment and 4 of the 18 metrics (6%) represented
a decline in pitching performance (Table IV). One of
these metrics that might be particularly relevant to
pitching performance was hard pitch maximum velocity, where direct analysis of the 8- to 12-wk time-

period scenario revealed a decline from 93.1 ± 1.0
miles/hr before surgery to 92.5 ± 0.9 miles/hr after
surgery (P ¼ 0.047, Wilcoxon matched-pairs signedrank test). Data shown in Figure 5 illustrate that these
beforeeafter differences were considered significant
for only 3 of the 9 pitchers (3, 4, and 8), whereas
the comparisons for pitchers 2, 5, 6, 7, 9, and
10 were not significantly different (ManneWhitney
U-tests).

DISCUSSION
In this study, we utilized analysis of traditional and
advanced pitching performance metrics for a series
of professional baseball pitchers returning to MLB
after surgery for NTOS. The results demonstrate
that this cohort exhibited postoperative pitching
performance capabilities largely equivalent to or
better than those exhibited before surgical treatment. This provides the first such evidence that
thoracic outlet decompression, along with an ample
period of postoperative rehabilitation, can provide
effective treatment for professional baseball pitchers
with career-threatening NTOS.
While this study represents the first analysis of
professional baseball pitchers that have returned to
MLB after treatment for NTOS, it remains limited
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Table III. Summary results for advanced pitching performance metrics, other time-period scenarios
Time period before
leave for surgery

Time period after return
from surgery

Abbreviation used

Number of significant
relationships observed

12 months
12 months
12 months
12 months
12 months
6 months
6 months
6 months
6 months
6 months
12 weeks
12 weeks
12 weeks
12 weeks
12 weeks
8 weeks
8 weeks
8 weeks
8 weeks
8 weeks
4 weeks
4 weeks
4 weeks
4 weeks
4 weeks

4 weeks
8 weeks
12 weeks
6 months
12 months
4 weeks
8 weeks
12 weeks
6 months
12 months
4 weeks
8 weeks
12 weeks
6 months
12 months
4 weeks
8 weeks
12 weeks
6 months
12 months
4 weeks
8 weeks
12 weeks
6 months
12 months

12 months to 4 weeks
12 months to 8 weeks
12 months to 12 weeks
12 months to 6 months
12 months to 12 months
6 months to 4 weeks
6 months to 8 weeks
6 months to 12 weeks
6 months to 6 months
6 months to 12 months
12 weeks to 4 weeks
12 weeks to 8 weeks
12 weeks to 12 weeks
12 weeks to 6 months
12 weeks to 12 months
8 weeks to 4 weeks
8 weeks to 8 weeks
8 weeks to 12 weeks
8 weeks to 6 months
8 weeks to 12 months
4 weeks to 4 weeks
4 weeks to 8 weeks
4 weeks to 12 weeks
4 weeks to 6 months
4 weeks to 12 months

4
7
11
9
9
8
11
14
8
8
10
17
16
12
11
10
14
18
10
10
6
5
6
6
6

Twenty-five different time-period scenarios were selected for detailed analysis of beforeeafter surgery comparisons of 72 advanced
performance metrics for 9 MLB pitchers undergoing surgical treatment for NTOS (in total, approximately 1800 time-period
scenarios and performance metrics were used as variables for analysis). By paired t-tests and Wilcoxon matched-pairs signed-rank
tests, there were a total of 247 significant relationships detected among the permutations analyzed. The data shown indicate the
number of significant relationships detected for different time-period scenarios, with the 8- to 12-week scenario having the highest
number (18, 25% of the 72 metrics analyzed).

by the small number of subjects available for analysis. Only 10 of the 13 pitchers (77%) who have undergone surgical treatment for NTOS exhibited a
successful return to play at the MLB level for which
there were appropriate data available, so the study
group was necessarily biased toward those with successful outcomes from surgery. It is not known why
other individuals did not achieve a return to MLB,
or if this was related to NTOS or other factors. In
addition, it is not entirely clear why the individuals
who retired during the study period chose to end
their MLB careers despite an apparently successful
return from surgery for NTOS. Another limitation
is the lack of information on additional injuries
that might have affected individual pitchers and
thereby influenced their performance, beyond any
limitations that might be attributed to NTOS.
The small number of pitchers described in this
study undoubtedly reflects the relatively rare

occurrence of NTOS compared with other conditions more frequently affecting MLB pitchers, such
as shoulder or ulnar collateral ligament injuries, as
well as the difficulty in diagnosis and possible reluctance to consider surgical treatment for NTOS in
elite athletes. The majority of the individuals in
this study (8 of 10) underwent surgical treatment after 2010, suggesting that there has been increasing
recognition of NTOS and appreciation for the potential benefits of surgical treatment. It remains unclear
if this might also reflect an actual increase in the
prevalence of NTOS in elite athletes, but this is
possible given the rigor of contemporary sports
training, high performance expectations, and the
frequency of upper extremity injury.
This study is unique with regard to the approach
used to assess surgical outcomes. Measures used to
evaluate results of treatment for NTOS are usually
semiquantitative patient-reported assessments of
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Table IV. Significant relationships for the 8- to 12-week time-period scenario
Pitch type

Pitching variable

Eight weeks before
(mean ± SEM)

Twelve weeks after
(mean ± SEM)

Eight week to twelve week
difference

P value

All
All
Hard
Hard
Breaking
Breaking
Breaking
Breaking
Breaking
Sinker
Sinker
Sinker
Sinker
Sinker
Curveball
Curveball
Curveball
Slider

FB/BF
GB/BF
MaxV
OBA
FB/BIP
GB/BIP
HorzM
OBA
OSLG
Wf/Sw
MaxV
FB/BIP
OBA
OSLG
GB/BIP
HorzM
OBA
VertM + G

0.25
0.32
93.12
0.303
23.29
33.26
3.41
0.226
0.343
5.08
92.93
18.83
0.336
0.521
27.95
2.39
0.192
39.27

0.23
0.36
92.50
0.265
10.42
43.09
4.08
0.167
0.229
3.57
92.31
11.57
0.228
0.347
41.09
3.10
0.123
36.36

0.03
0.03
0.62
0.04
12.87
9.83
0.67
0.06
0.11
3.64
0.62
7.27
0.11
0.11
13.15
0.71
0.07
2.91

0.047a
0.040a
0.025b
0.007a
0.008a
0.009a
0.015a
0.023a
0.002a
0.040b
0.011b
0.013b
0.012a
0.012a
0.038a
0.042a
0.014a
0.022a

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.02
0.03
1.03
0.014
3.81
5.73
1.26
0.028
0.047
0.28
0.99
1.80
0.040
0.035
8.01
1.36
0.041
2.04

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.03
0.03
0.93
0.021
3.22
6.96
1.25
0.019
0.029
0.45
0.97
2.84
0.036
0.045
7.15
1.44
0.034
2.17

±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±
±

0.01
0.01
0.23
0.01
3.69
2.88
0.21
0.02
0.03
1.40
0.17
2.07
0.03
0.03
5.15
0.29
0.02
0.44

Specific advanced performance metrics exhibiting significant differences in analysis of the 8- to 12-week time-period scenario for 9
MLB pitchers undergoing surgical treatment for NTOS. Fifty-four of 72 metrics (75%) analyzed were unchanged (not shown,
including ERA, WHIP, and SO/BB). Fourteen metrics (19%) with a significant difference represented an improvement in pitching
performance after the return from surgical treatment for NTOS. Four of the 18 metrics (6%) with a significant difference
represented a decline in pitching performance.
FB/BF, flyball per batter faced; FB/BIP, flyball per ball in play; GB/BF, groundball per batter faced; GB/BIP, groundball per ball in play;
HorzM, horizontal movement (inches); MaxV, maximum velocity (miles/hr); OBA, opponent batting average; OSLG, opponent
slugging percentage; SEM, standard error of the mean; VertM + G, vertical movement plus gravity (inches); Wf/Sw, whiff per swing.
a
Difference designates improved pitching performance.
b
Difference designates diminished pitching performance.

pain and functional disability, which can be relatively subjective as well as highly variable.4e6 The
abundance of objective performance measures
available in professional baseball thereby allows an
opportunity to assess the sport-specific outcomes
of surgery for NTOS in a manner independent of
subjective symptoms. Professional baseball pitchers
are certainly not typical of patients with NTOS,
without having had the magnitude or duration of
disability often exhibited by those with this condition, and the outcomes in professional baseball
pitchers cannot be extrapolated to other populations
of patients. Nonetheless, NTOS in an MLB pitcher is
a career-threatening development as it prevents
satisfactory performance and does not respond
well to conservative therapy. Thus, an important
conclusion from this study is that successful outcomes can still be achieved with surgical treatment
for NTOS, even in a patient population with particularly demanding occupational requirements.
It is valuable in considering the findings of this
study to distinguish between the various statistical
metrics and how they might reflect different aspects
of baseball pitching performance following surgical

treatment. For example, ‘‘counting’’ metrics (e.g.,
G, IP) largely reflect playing opportunity and pitcher
durability and ‘‘aggregate’’ metrics (e.g., HR)
depend on opponent performance, whereas
‘‘descriptive’’ metrics (e.g., AvgV, MaxV) most
directly reflect health and level of performance
and ‘‘rate’’ metrics (e.g., SO%, WHIP) more closely
reflect pitching skill and effectiveness. Metrics that
depend on opponent hits or runs are thereby unsatisfactory in evaluating pitching recovery and performance, and it is more valuable to emphasize metrics
that are under the more direct control of the pitcher.
Pitching performance metrics may also be separated
into those that assess throwing strength (pitch velocity) and those that assess fine neurological motor
function (pitch control), because velocity and control may return at different phases of recovery
from surgery. Furthermore, some of the metrics
assessed here predominantly reflect the style of an
individual pitcher rather than talent or performance. For example, the proportion of fly balls
versus ground balls reveals the general tendencies
of hitters against a given pitcher, based on the types
of pitches thrown and different game situations, and
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Fig. 5. Individual comparisons of hard pitch maximum
velocity for the 8- to 12-week time-period scenario.
Hard pitch maximum velocity (PitchF/x advanced
pitch metrics) for 9 MLB pitchers, in direct analysis of
the 8- to 12-week time-period scenario. Data shown
illustrate the mean ± SEM maximum velocity for each
pitcher along with the number of games played and
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innings pitched during each interval. The beforeeafter
differences were considered significant for 3 of the 9
pitchers (3, 4, and 8), whereas comparisons for the
remaining pitchers (2, 5, 6, 7, 9, and 10) were not significantly different (ManneWhitney U-tests). SEM, standard error of the mean.
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may not provide insight into the level of skill or
pitching performance. Indeed, pitcher style may
change over time and some may choose to change
their pitching repertoire during the course of their
careers. Finally, baseball organizations often use aging curves to predict the decline or rise of player performance over time. While pitching performance is
expected to diminish with age, players who have
been able to return to the same level of performance
after a long period of recovery from surgery may
actually be considered to be improved given their
concomitant increase in age. These factors will all
be useful considerations for future research.
One of the most valuable insights from this study
is the apparent importance of gradual recovery and
postoperative rehabilitation, with most pitchers
requiring close to a year after surgery to return to
game-ready MLB performance. This is similar to the
recovery period expected for MLB pitchers undergoing ulnar collateral ligament reconstruction, where
attempts to recover more rapidly can be predicted
to have less successful outcomes and a higher rate
of recurrent injury.22e26 Many of the individuals in
this study appear likely to have had some degree of
NTOS symptoms for one or more seasons before diagnosis, along with multiple forms of treatment and
previous operations, without addressing the underlying source of disability. These pitchers may have tried
to play through considerable symptoms without success, with surgery for NTOS undertaken only as a
‘‘last resort’’ before considering retirement. While
the inciting cause of chronic brachial plexus
compression injury may be alleviated by thoracic
outlet decompression, neural healing is an extremely
slow process that may only begin once decompression is accomplished. Furthermore, patients with
longstanding NTOS develop compensatory alterations in posture and shoulder girdle mechanics to
minimize brachial plexus nerve irritation. These adaptations may cause additional secondary symptoms,
such as sustained spasm in the rhomboid, trapezius,
and posterior neck muscles. Because surgical treatment for NTOS does not necessarily alter chronic
neural injury or compensatory alterations, physical
therapy remains a crucial part of recovery to retrain
associated muscle groups and to improve shoulder
girdle biomechanics. This is likely another major
reason that recovery from surgery for NTOS can
take much longer than might be expected, a factor
likely to be magnified in MLB pitchers.
This study suggests a number of directions for
future research. While there have been similar
studies on MLB pitchers examining return to play
and performance metrics after ulnar collateral ligament repair, investigators have also begun to
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examine specific alterations in pitching biomechanics in pitchers who have undergone such operations.27,28 It would therefore be of interest to
examine if pitchers recovered from surgery for
NTOS have any consistent or sustained alterations
in shoulder girdle or throwing biomechanics. There
have also been attempts to identify sabermetric parameters or profiles associated with subsequent
injury or time on the disabled list due to shoulder
or elbow injuries, raising the possibility that there
might be similar sabermetric profiles of pitchers at
risk for developing NTOS.29e31 Finally, it is notable
that the subjects of this study typically underwent
surgery for NTOS after a period of declining performance and a protracted search for diagnosis, which
may have adversely affected recovery from surgery.
It remains possible that with earlier diagnosis and
prompt surgical treatment, more rapid recovery
and rehabilitation may be feasible than observed
in the present cohort. Efforts to provide earlier diagnosis of NTOS, such as with exercise-enhanced
scalene muscle anesthetic blocks,32,33 may help
improve results from physical therapy, use of alternative approaches (e.g., scalene muscle injections
with botulinum toxin),34,35 or different forms of
surgical treatment.36

CONCLUSIONS
Based on the analysis of traditional and advanced
pitching metrics, the performance of professional
baseball pitchers who returned to MLB after surgery
for NTOS was similar to their performance before
treatment. Thoracic outlet decompression and
postoperative rehabilitation can provide effective
treatment for professional baseball pitchers with
career-threatening NTOS.
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